{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T19:37:54Z","timestamp":1772998674115,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As no randomized study has compared abiraterone acetate (ABI) doublet and triplet therapy, the optimal target for the add\u2010on of docetaxel (DTX) to ABI doublet therapy remains unclear. The present study explored patients who may benefit from add\u2010on DTX using initial prostate\u2010specific antigen (PSA) reduction after ABI doublet therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively reviewed 233 patients with CHAATED high\u2010volume metastatic castration\u2010sensitive prostate cancer (mCSPC) treated with ABI doublet therapy. Using the initial PSA half\u2010life calculated by PSA reduction within 6 weeks of treatment (initial PSA\n                      <jats:sup>T1\/2<\/jats:sup>\n                      ), a subgroup of patients with a poor overall survival (OS) was explored. The optimal cutoff value of PSA\n                      <jats:sup>T1\/2<\/jats:sup>\n                      predicting a PSA decline &lt;\u200990% after 12 weeks of ABI treatment was investigated using a receiver operating characteristic (ROC) analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A PSA\n                      <jats:sup>T1\/2<\/jats:sup>\n                      of 0.33 months was an ideal cutoff value for predicting a PSA decline &lt;\u200990% after 12 weeks of ABI treatment. In addition to Grade Group 5 (hazard ratio [HR]: 3.06,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) and an LDH\u2009\u2265\u2009250\u2009U\/L (HR: 2.30,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017), an initial PSA\n                      <jats:sup>T1\/2<\/jats:sup>\n                      \u2009\u2265\u20090.33 months (HR: 3.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) were identified as significant predictors of a poor OS in mCSPC treated with ABI doublet therapy. Only liver metastasis was significantly associated with an initial PSA\n                      <jats:sup>T1\/2<\/jats:sup>\n                      of \u2265\u20090.33 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      We showed that the initial PSA\n                      <jats:sup>T1\/2<\/jats:sup>\n                      of treatment was significantly prognostic in high\u2010volume mCSPC patients treated with ABI doublet therapy. Our findings suggest that initial PSA reduction may help identify patients who will benefit from the addition of DTX. A prospective study is required to verify our hypotheses.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.70127","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T16:10:41Z","timestamp":1768752641000},"page":"609-615","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Impact of Initial Prostate Specific Antigen Half\u2010Life After Abiraterone Acetate in High\u2010Volume Metastatic Hormone\u2010Sensitive Prostate Cancer: Who May Need Triplet Therapy?"],"prefix":"10.1002","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4589-9251","authenticated-orcid":false,"given":"Kotaro","family":"Suzuki","sequence":"first","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7742-4528","authenticated-orcid":false,"given":"Hideto","family":"Ueki","sequence":"additional","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Wakita","sequence":"additional","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyoshi","family":"Okamura","sequence":"additional","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Bando","sequence":"additional","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Hara","sequence":"additional","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-6516","authenticated-orcid":false,"given":"Tomoaki","family":"Terakawa","sequence":"additional","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9553-0981","authenticated-orcid":false,"given":"Yoji","family":"Hyodo","sequence":"additional","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Chiba","sequence":"additional","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7018-5095","authenticated-orcid":false,"given":"Jun","family":"Teishima","sequence":"additional","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Miyake","sequence":"additional","affiliation":[{"name":"Division of Urology Kobe University Graduate School of Medicine Kobe Hyogo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,1,18]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32630"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00799"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715546"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00367-1"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.02.009"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16449"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24847"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.8751"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20627"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.12.4487"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01798"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7762"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-024-02485-4"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.15657"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2022.04.007"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.09.030"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00063-3"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35819"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.11.026"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003594"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00609-3"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.003"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.06.010"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.07.026"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.70127","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:55:20Z","timestamp":1772988920000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.70127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,18]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/pros.70127"],"URL":"https:\/\/doi.org\/10.1002\/pros.70127","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,18]]},"assertion":[{"value":"2025-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}